Accéder au contenu
Merck

[Treatment of vestibular vertigo and Ménière syndrome in outpatient clinics].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2013-02-08)
E V Kostenko, L V Petrova, E A Torgovanova, P A Ganzhula, L N Lisenker, O V Otcheskaia, A A Khozova, A V Lebedeva, A N Boĭko
RÉSUMÉ

An aim of this study was to assess clinical efficacy and tolerability of tagista in the symptomatic treatment of vestibular vertigo and Ménière syndrome. Thirty-two patients, 16 women and 16 men, aged from 25 to 67 years, were examined. Vertigo was caused by chronic brain ischemia in 17 cases and by the disturbance of blood circulation in the vertebral-basilar system in 14 patients with osteochondrosis of cervical spine. One patient was diagnosed with Ménière syndrome. Tagista was used in dose 24 mg twice a day during 4 weeks in the combination with standard treatment, exercise therapy and stability training. The results revealed a statistically significant effect of the drug on main symptoms (frequency, duration and intensity of vertigo attacks etc) and its good tolerability that allowed to recommend the drug in neurological practice.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Betahistine dihydrochloride, ≥98%
Sigma-Aldrich
2-(2-Methylaminoethyl)pyridine, 97%
Betahistine mesilate, European Pharmacopoeia (EP) Reference Standard